Etude : SHR3162-III-305 / FUZUPRO



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme / Nom
Situation thérapeutique
Traitement
Cadre réglementaire
MÀJ
Présentation de l'étude
Acronyme / Nom : SHR3162-III-305 / FUZUPRO

Situation thérapeutique : Métastatique ou localement avancé

Traitement : Thérapie ciblée

Cadre réglementaire : RIPH1

Dernière MÀJ : 29/11/2021
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Spécialité : Organes génitaux masculins
Localisation : C61 - Tumeur maligne de la prostate
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : STUDY ARMS:
- Experimental: Treatment group A - Fuzuloparib plus AA-P
1. Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po
2. Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po
3. Prednisone tablets (strength: 5 mg) 5mg, Bid po

- Placebo Comparator: Treatment group B - Fuzuloparib Placebo plus AA-P
1. Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po
2. Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po
3. Prednisone tablets (strength: 5 mg)5mg, Bid po

MAIN OBJECTIVE:
- To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1)
- to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).

SECONDARY OBJECTIVES:
To evaluate the OS in unselected mCRPC subjects (Cohort 1) and in mCRPC subjects harboring DRD (Cohort 2), respectively.

Phase : III

Stade : Métastatique

1 (hémato)
Informations libres de droit
Critères d'inclusion
Critères de non-inclusion
Informations libres de droit
Critères d'inclusion et de non-inclusion
Critères d'inclusion : 1) Age of ≥ 18 years old.
2) A score of 0 to 1 for ECOG performance status.
3) Expected survival of ≥ 6 months.
4) Prostate adenocarcinoma confirmed by histology or cytology examinations, with no indication of neuroendocrine differentiation or small cell characteristics.
5) Metastatic lesions with imaging evidence.
6) Disease progression of metastatic prostate cancer while the subject was on androgen deprivation therapy. See the disease progression at study entry definition in the protocol.
7) Continuous treatment with luteinizing hormone-releasing hormone analogue (LHRHa) (drug-induced castration) or previous bilateral orchidectomy (surgical castration); subjects who have not undergone bilateral orchidectomy must plan to maintain effective LHRHa treatment within 4 weeks prior to the randomization of this study and throughout the entire study.
8) Testosterone is at the castration level (≤ 50 ng/dL or 1.73 nmol/L) during screening.
9) Blood and tumor tissue samples (tumor sample is optional) are provided during screening to determine the DRD status; subjects in Cohort 2 must be DRD positive.
10) The functional level of the organs must meet the requirements (no blood transfusion or treatment with hematopoietic growth factor within 2 weeks prior to routine blood screening) as detailed in the protocol.
11) For patients who are judged by the investigator as having the ability to ejaculate and who are sexually active must agree to take effective contraceptive measures and not to donate sperm from the first dose to 3 months after the last dose of study treatment.
12) Participate in this clinical trial voluntarily, understand and have signed the informed consent.

Critères de non-inclusion : 1) Prior treatment with any PARP inhibitor.
2) Have received any systemic anti-tumor treatment during the mCRPC stage or non-metastatic CRPC (nmCRPC) stage, including chemotherapy, immunotherapy, abiraterone acetate or other CYP17 inhibitors, novel AR antagonists (such as enzalutamide, apalutamide, darolutamide, SHR3680, and proxalutamide) and other molecular targeted therapies. See protocol for the allowed exceptions.
3) With severe bone injury caused by bone metastasis of prostate cancer as judged by the investigator, including poorly controlled severe bone pain, and pathological fractures and spinal cord compressions that have occurred in the last 6 months before the first dose or are expected to occur soon.
4) Radiotherapy or major surgery within 3 weeks before the first dose, or participation in other drug clinical trials within 4 weeks or 5 half-lives, whichever is longer, prior to start of this study drug at day 1 (C1D1).
5) Have used any strong/moderate CYP3A4 inducers or inhibitors within 14 days prior to the first dose.
6) The use of drugs that may affect P-gp cannot be interrupted during the study.
7) Plan to receive any other anti-tumor treatment during the study treatment of this study.
8) Presence of radiologically confirmed tumor lesions in the brain.
9) Contraindications to the use of prednisone (corticosteroids), such as active infections or other medical conditions.
10) Any chronic medical conditions that require a dose of corticosteroid ≥ 5 mg prednisone BID.
11) History of uncontrolled pituitary or adrenal dysfunction.
12) Uncontrolled hypertension (persistent systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg). Subjects with a history of hypertension are allowed to participate in the study if their blood pressure can be effectively controlled by antihypertensive therapy.
13) Presence of active heart diseases (including severe/unstable angina pectoris, symptomatic congestive heart failure of NYHA Class III or IV, left ventricular ejection fraction < 50%, and ventricular arrhythmia requiring drug therapy) or a history of arterial or venous thrombosis (including pulmonary embolism and cerebrovascular accident) within 6 months, or myocardial infarction within 12 months prior to the first dose.
14) History of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), or a history of other malignant tumors within 5 years prior to the first dose (except carcinoma in situ that has been completely relieved and the malignant tumor that is judged by investigators as slowly progressive).
15) Active HBV or HCV infection (HBsAg positive with virus copy ≥ 500 IU/mL, HCV antibody positive with HCV RNA higher than the lower limit of detection of the analytical method).
16) Human immunodeficiency virus-positive subjects with 1 or more of the following:
- Not receiving highly active antiretroviral therapy.
- Had a change in antiretroviral therapy within 6 months of the start of screening.
- Receiving antiretroviral therapy that may interfere with study drug (consult sponsor for review of medication prior to enrollment).
- CD4 count < 350/mm3 at screening.
- AIDS-defining opportunistic infection within 12 months of start of screening.
17) Presence of dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption.
18) With known allergy or intolerance to fuzuloparib, abiraterone acetate, prednisone, or their excipients.
19) Confirmed SARS-CoV-2 (COVID-19) infection (validated test positive), or suspected COVID-19 infection (clinical symptoms without documented test results), or close contact with a person with known or suspected COVID-19 infection, within 4 weeks before the first dose. The subject may be included with a documented negative result for a validated COVID-19 test.
20) Presence of concomitant diseases (such as severe diabetes mellitus, thyroid disorder, and psychiatric disorders) or any other situation that may pose serious risks to the safety of the subjects or may affect their ability to complete the study as judged by the investigator.
NCT
Promoteur
Coordonnateur
Informations relatives au promoteur
NCT :
NCT04691804
Promoteur :
Jiangsu HengRui Medicine
Type de sponsor : Industriel
Jiangsu HengRui Medicine
00000 HORS FRANCE

Coordonnateur :
Centre investigateur
Investigateur
TEC / ARC / IDE
État
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
Centre Hospitalier Universitaire de Lille - 2 Avenue Oscar Lambret - 59000 LILLE

Investigateur :
Professeur Arnauld Villers

TEC / ARC / IDE :
Jérémy DRUGEON
Jeremy.DRUGEON@
CHRU-LILLE.FR
+33 (0)3.20.44.59.62, Poste 30049

Statut de l'essai : À VENIR

MAJ : 16/09/2021